Sellas Life Sciences is trading 5.6% up today at $10.66 as investors refocus on the company's $138.3 million cash position and upcoming clinical milestones.
- The stock is rebounding from recent post-earnings volatility, with the current cash runway now projected to last through late 2028.
- Market attention is shifting toward the final 80-event trigger in the Phase 3 REGAL trial for galinpepimut-S, which has been a primary driver of speculative interest.